<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="124969">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01475643</url>
  </required_header>
  <id_info>
    <org_study_id>670</org_study_id>
    <nct_id>NCT01475643</nct_id>
  </id_info>
  <brief_title>Loteprednol vs Prednisolone for the Treatment of Intraocular Inflammation Following Cataract Surgery in Children.</brief_title>
  <official_title>Safety and Efficacy of Topical Loteprednol Etabonate 0.5%, Versus Prednisolone Acetate 1%, for the Treatment of Intraocular Inflammation Following Surgery for Childhood Cataract</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bausch &amp; Lomb Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bausch &amp; Lomb Incorporated</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to compare the efficacy and safety for the treatment of
      postoperative inflammation following ocular surgery for childhood cataract.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this study is to compare the efficacy and safety of topical Loteprednol
      Etabonate (LE), 0.5%, to Prednisolone Acetate 1%, for the treatment of postoperative
      inflammation following ocular surgery for childhood cataract.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Care Provider, Investigator</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Anterior Chamber Inflammation</measure>
    <time_frame>Postoperative Day 29</time_frame>
    <description>Mean grade of converted anterior chamber inflammation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anterior Chamber Cells &amp; Flare</measure>
    <time_frame>Over all visits 42 days</time_frame>
    <description>Proportion of subjects with anterior chamber inflammation.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">170</enrollment>
  <condition>Cataract</condition>
  <arm_group>
    <arm_group_label>Loteprednol etabonate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Loteprednol etabonate 0.5%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prednisolones acetate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Prednisolone acetate 1.0%</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Loteprednol etabonate</intervention_name>
    <description>1-2 Ophthalmic drops administered to study eye four times daily (QID) for 14 days post surgery. Tapered to twice daily (BID) for 7 days. Then once daily (QD) for 7 days.</description>
    <arm_group_label>Loteprednol etabonate</arm_group_label>
    <other_name>LE</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolones acetate</intervention_name>
    <description>1-2 Ophthalmic drops administered to study eye four times daily (QID) for 14 days post surgery. Tapered to twice daily (BID) for 7 days. Then once daily (QD) for 7 days.</description>
    <arm_group_label>Prednisolones acetate</arm_group_label>
    <other_name>PA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is a candidate for routine, uncomplicated surgery for childhood cataract

        Exclusion Criteria:

          -  Subjects who have a severe/serious ocular condition, or any other unstable medical
             condition that, in the Investigator's opinion, may preclude study treatment or
             follow-up.

          -  Subjects with glaucoma, ocular hypertension, or those receiving intraocular pressure
             (IOP) lowering therapy in either eye or systemically.

          -  Subjects with a history of steroid-induced IOP elevation in either eye.

          -  Subjects who have known hypersensitivity or other contraindication to the study
             drug(s) or any components in the drug formulation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>11 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johnson Varughese</last_name>
    <role>Study Director</role>
    <affiliation>Valeant/Bausch &amp; Lomb</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Johnson Varughese</last_name>
    <phone>908-927-1162</phone>
    <email>johnson.varughese@valeant.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Bausch &amp; Lomb Inc</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14609</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 8, 2017</lastchanged_date>
  <firstreceived_date>November 17, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pediatric cataract</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Cataract</mesh_term>
    <mesh_term>Uveitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Loteprednol Etabonate</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
